These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38066860)

  • 21. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
    Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.
    Park S; Kim TY; Cho BS; Kwag D; Lee JM; Kim M; Kim Y; Koo J; Raman A; Kim TK; Kim HJ
    Haematologica; 2024 Apr; 109(4):1095-1106. PubMed ID: 37706344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 27. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
    Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
    Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
    Pollyea DA; Winters A; McMahon C; Schwartz M; Jordan CT; Rabinovitch R; Abbott D; Smith CA; Gutman JA
    Bone Marrow Transplant; 2022 Feb; 57(2):160-166. PubMed ID: 34645926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
    Gangat N; Tefferi A
    Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
    Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
    J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
    Xu X; Liu R; He A; Wang F
    Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancements and Challenges in the Treatment of AML.
    Abaza Y; McMahon C; Garcia JS
    Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e438662. PubMed ID: 38662975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
    Kamachi K; Ureshino H; Watanabe T; Yoshida-Sakai N; Fukuda-Kurahashi Y; Kawasoe K; Hoshiko T; Yamamoto Y; Kurahashi Y; Kimura S
    Cancer Res Commun; 2023 Feb; 3(2):297-308. PubMed ID: 36860654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
    Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapies upon failure of HMA plus venetoclax.
    Chan O; Walker AR
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):702-708. PubMed ID: 38066883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Khouderchah CJ; Benitez LL; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ
    Leuk Lymphoma; 2024 Feb; 65(2):228-234. PubMed ID: 37933203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
    Levitz D; Saunthararajah Y; Fedorov K; Shapiro LC; Mantzaris I; Shastri A; Kornblum N; Sica RA; Shah N; Konopleva M; Gritsman K; Braunschweig I; Cooper DL; Pradhan K; Verma A; Feldman EJ; Goldfinger M
    Clin Cancer Res; 2023 Aug; 29(15):2774-2780. PubMed ID: 37341641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.